In another study with PSMA-617, the addition of the IP-ABM also resulted in twofold higher accumulation in tumor tissue as compared to the non-ABM containing PSMA-617 agent (non-ABM PSMA-617: 38% ID/g vs. IP-ABM PSMA-617: 75.7% ID/g at 24 h) [28,57]. Here, FOLH1 is linked to neoplasm.